Larimar Therapeutics, Inc.
LRMRNasdaq
$3.70
↑ +0.8%Jul 17 close · end-of-day
Price
1Y↑ +15.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$166.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-105.0%
ROIC
—
Debt / Equity
—
Net Cash
$200.4M
Return 1Y
+11.5%
Company profile
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia.
- CEO
- Carole S. Ben-Maimon
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- Pennsylvania
- Website
- larimartx.com
Management & directors
- Ben-Maimon CarolePresident and CEO
- Celano MichaelChief Financial Officer
- Clayton RussellChief Medical Officer
- Shankar GopiChief Development Officer
Roles derived from SEC Form 4 filings.
Earnings
LRMR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$42.8M | -$50.5M | -$36.5M | -$41.8M | -$90.9M | -$172.5M |
| Net income | -$42.5M | -$50.6M | -$35.4M | -$36.9M | -$80.6M | -$165.7M |
| Diluted EPS | -$3.57 | -$2.95 | -$1.37 | -$0.84 | -$1.32 | — |
| Operating cash flow | -$42.2M | -$42.1M | -$27.6M | -$33.5M | -$70.8M | -$113.2M |
| Free cash flow | -$42.3M | -$42.4M | -$27.7M | -$33.6M | -$71.3M | -$113.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$24.6M | -$18.3M | -$31.3M | -$31.2M | -$27.8M | -$49.5M | -$64.0M | -$31.1M |
| Net income | -$21.6M | -$15.5M | -$28.8M | -$29.3M | -$26.2M | -$47.7M | -$62.5M | -$29.6M |
| Diluted EPS | -$0.34 | -$0.24 | -$0.47 | -$0.46 | -$0.41 | -$0.61 | — | — |
| Operating cash flow | -$14.0M | -$24.5M | -$21.8M | -$26.5M | -$19.4M | — | — | -$44.6M |
| Free cash flow | — | -$24.6M | — | -$26.6M | -$19.4M | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
Jul 2, 2026
Jun 29, 2026
- 21d agoLarimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)investorshub.advfn.com
- 21d agoLarimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Knowstocktwits.com
- 21d agoLarimar Therapeutics Files First Module of BLA With US FDA for Nomlabofuspfinance.yahoo.com
- 21d agoLarimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxiafinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Hamilton Thomas Edward | Buy | 50,000 | $3.34 | $166,890.00 | filing |
| 2026-02-27 | Flynn James E | Buy | 2,000,000 | $5.00 | $10.0M | filing |
| 2026-02-27 | Flynn James E | Buy | 1,084,012 | $5.00 | $5.4M | filing |
| 2026-02-27 | Flynn James E | Buy | 1,084,010 | $5.00 | $5.4M | filing |
| 2026-02-27 | Flynn James E | Buy | 831,978 | $5.00 | $4.2M | filing |
| 2026-02-27 | Hamilton Thomas Edward | Buy | 100,000 | $5.00 | $500,000.00 | filing |
| 2026-02-27 | SHERMAN JEFFREY W | Buy | 5,000 | $5.00 | $25,000.00 | filing |
| 2026-02-27 | THOMAS FRANK E | Buy | 5,000 | $5.00 | $25,000.00 | filing |
| 2026-01-26 | Celano Michael· Chief Financial Officer | Award | 37,604 | $0.00 | $0.00 | filing |
| 2026-01-26 | Clayton Russell· Chief Medical Officer | Award | 25,637 | $0.00 | $0.00 | filing |
| 2026-01-26 | BEN-MAIMON CAROLE· President and CEO | Award | 100,100 | $0.00 | $0.00 | filing |
| 2026-01-26 | Shankar Gopi· Chief Development Officer | Award | 25,637 | $0.00 | $0.00 | filing |
| 2025-07-31 | Flynn James E | Buy | 3,387,539 | $3.20 | $10.8M | filing |
| 2025-07-31 | Flynn James E | Buy | 3,387,529 | $3.20 | $10.8M | filing |
| 2025-07-31 | Flynn James E | Buy | 2,599,932 | $3.20 | $8.3M | filing |
Latest 15 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.